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A B S T R A C T
Aicardi-Goutières syndrome (AGS) is an early-onset monogenic encephalopathy characterized by intracranial calcification, leukodystrophy and cerebrospinal fluid
lymphocytosis. To date, seven genes have been related to AGS. Among these, IFIH1 encodes for MDA5, a cytosolic double-stranded RNA receptor, and is responsible
for AGS type 7. We generated three isogenic iPSC clones, using a Sendai virus-based vector, starting from fibroblasts of a patient carrying a dominant mutation in
IFIH1. All lines were characterized for genomic integrity, genetic uniqueness, pluripotency, and differentiation capability. Our clones might offer a good model to
investigate AGS7 pathophysiological mechanism and to discover new biomarkers for this condition treatment.
Resource Table
Unique stem cell lines identifier UNIBSi009-A
UNIBSi009-B
UNIBSi009-C
Alternative names of stem cell lines AGS7-GS-C3.A (UNIBSi009-A)
AGS7-GS-C6.4 (UNIBSi009-B)
AGS7-GS-C7.4 (UNIBSi009-C)
Institution "Angelo Nocivelli" Institute for Molecular Medicine, Department of Molecular and Translational Medicine, University of Brescia,
25123 Brescia, Italy
Contact information of distributor Stefania Masneri: s.masneri003@unibs.it
Type of cell lines iPSC
Origin Human
Additional origin info Age: 14 years
Sex: male
Ethnicity: Caucasian
Clonality Clonal
Method of reprogramming CytoTune™-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher Scientific). The episomal reprogramming vectors include the four
Yamanaka factors OCT4, SOX2, KLF4, and C-MYC
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1. Resource utility
Aicardi-Goutières Syndrome type 7 (AGS7) is an autosomal domi-
nant inflammatory disorder characterized by severe neurologic im-
pairment, due to mutations in IFIH1 gene, encoding for MDA5, a cy-
tosolic double-stranded RNA receptor. The AGS7 specific iPSC lines
could be a suitable tool for in vitro disease modelling, and early bio-
markers discovering.
2. Resource details
Aicardi-Goutières Syndrome (AGS) is an early-onset genetically
determined encephalopathy, characterized by intracranial calcification,
leukodystrophy and cerebrospinal fluid lymphocytosis. To date, seven
genes, encoding for proteins involved in nucleic acids metabolism and
sensing (TREX1, RNASEH2B, RNASEH2C, RNASEH2A, ADAR1,
SAMHD1, IFIH1) have been related with an AGS phenotype. Among
these, IFIH1 (interferon-induced helicase c domain-containing protein
1) encodes for MDA5, a cytosolic double-stranded RNA receptor mu-
tated in AGS7 (OMIM 615846) (Crow et al., 2019; Garau et al., 2019;
Amari et al., 2019). Only 3–5% of the AGS cases are AGS7, thus much
remains to be discovered about its clinical course and features. IFIH1 is
essential in the mammalian immune system against viral infection, and
heterozygous gain-of-function mutations lead to increased levels of type
I interferons, causing the systemic manifestations of the disease
(Amari et al., 2019; Oda et al., 2014; Rice et al., 2014).
We reprogrammed fibroblasts of a 14 years old male carrying a
heterozygous dominant missense variant, placed within Helicase C-
terminal Domain (IFIH1:NM_022168.4:c.[2471G>A, =]:p.[R824K,
=]), using a Sendai virus-based vector delivering the four Yamanaka
factors OCT4, SOX2, KLF4, and c-MYC (CytoTune-iPS 2.0 Sendai
Reprogramming Kit, Thermo-Fisher Scientific) in feeder free conditions.
Three clones (UNIBSi009-A, UNIBSi009-B, and UNIBSi009-C, sum-
marized in Table 1) displaying an ESC-like morphology (Fig. 1A) were
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Qualitative analysis: Immunofluorescence Positive for pluripotency markers: OCT4, and TRA–1–60 Fig. 1 panel B
Quantitative analysis: TaqMan® Human
Pluripotent Stem Cell Scorecard™ analysis
All samples were found to be pluripotent and transgene free:
scored positive for self-renewal markers and negative for all
three trilineage markers
Fig. 1 panel D
Genotype Karyotype (G-banding) and resolution 46,XY.
Resolution 450–500
Supplementary Figure 1
Identity Microsatellite PCR (mPCR) OR STR analysis N/A N/A
STR analysis: 16 distinct loci: all matched to parental cell line Available with the
authors
Mutation analysis (IF
APPLICABLE)
Sequencing Heterozygous:
IFIH1 gene: c.[2471G>A, =]:p.[R824K, =]
Fig. 1 panel C
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma endpoint PCR negative Supplementary Figure 2
Differentiation potential Direct differentiation into three germ layers:
qPCR with TaqMan chemistry
C3.A:
positive for PAX6-SOX1 (Ectoderm), NCAM1-ACTA2
(Mesoderm), and GATA4-SOX17 (Endoderm).
C6.4 and C7.4:
positive for PAX6-SOX1 (Ectoderm), CXCR4-ACTA2
(Mesoderm), and GATA4-SOX17 (Endoderm).
Fig. 1 panel E
Donor screening (OPTIONAL) HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Multiline rationale Isogenic clones
Gene modification Congenital mutation
Type of modification N/A
Associated disease Aicardi Goutières Syndrome type 7 (AGS7)
Gene/locus IFIH1/Cytogenetic band: 2q24.2
Method of modification N/A
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date Jan 2016
Cell line repository/bank https://hpscreg.eu/user/cellline/edit/UNIBSi009-A
https://hpscreg.eu/user/cellline/edit/UNIBSi009-B
https://hpscreg.eu/user/cellline/edit/UNIBSi009-C
Ethical approval IRB Spedali Civili and University of Brescia, NP n.1603 -Studio AGS-CARIPLO
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
UNIBSi009-A C3.A male 14 Caucasian GA AGS7
UNIBSi009-B C6.4 male 14 Caucasian GA AGS7
UNIBSi009-C C7.4 male 14 Caucasian GA AGS7
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Fig. 1. A. iPSC clones morphology; scale bar = 1 mm. B. Immunofluorescence staining of iPSCs with the pluripotency markers Tra-1-60 (green) and Oct4 (red). Cell
nuclei were stained with Hoechst 33342 (blue), and the three channels were merged; scale bar = 100 µm. C. iPSCs genomic sequence, showing the missense variation
c.2471 G>A, marked with a black arrow. D. TaqMan hPSC Scorecard Report, displaying iPSCs pluripotency, using numerical values and the “Plus” “Minus” graphical
symbols. E. Gene expression analysis of three germ layers markers.
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chosen for characterization.
These selected iPSC lines were checked for genetic uniqueness by
short tandem repeat (STR) profiling against the parental fibroblasts
(Table 2) and for private mutation by targeted Sanger Sequencing
(Fig. 1C). Furthermore, iPSC lines were demonstrated to be myco-
plasma-free (Supplementary Fig.2) and retained a normal karyotype
(46,XY) (Supplementary Fig.1).
Pluripotency was assessed by immunofluorescence staining using
Tra-1–60 and OCT4, markers that are expressed on the cell surface, and
at nuclear level, respectively (Fig. 1B). Pluripotency characterization
was performed using TaqMan hPSC Scorecard Panel (Thermo-Fisher
Scientific). Scorecard analysis compares the expression of 94 genes of
an unknown sample with that of 13 ESC (Embryonic Stem Cell) and
iPSC control lines. The comparative analysis generates a reference value
called Pluripotency Score. In order that a cell line to be called plur-
ipotent, the score must be ≥ −0.5 for the self-renewal genes, and ≤
0.5 for the genes of the three embryonic germ layers. The UNIBSi009-A,
UNIBSi009-B, and UNIBSi009-C clones respect this condition and
therefore are to be considered pluripotent as shown in Fig. 1D, that
displays both the numerical values and the “Plus” “Minus” graphical
symbols, referring to the self-renewal and Ectoderm, Mesoderm, En-
doderm genes.
Finally, we verified the capability of iPSC clones to differentiate in
vitro into ectoderm, mesoderm and endoderm layers, using the com-
mercial StemMACS Trilineage Differentiation Kit (Miltenyi). We eval-
uated the gene expression of PAX6-SOX1, NCAM1-CXCR4-ACTA2,
GATA4-SOX17, specific for each germ layers, by TaqMan quantitative
PCR (Fig. 1E).
In conclusion, we generated three isogenic iPSC clones from a IFIH1
mutated patient which represent the first description to our knowledge
and can be considered an advanced in vitro model for AGS7. The iPSCs
differentiation towards neurons could help in proceed to a better un-
derstanding of this syndrome.
3. Materials and methods
3.1. Fibroblasts reprogramming
Fibroblasts of a 14 years-old male patient with AGS7 were cultured
in DMEM with 10% Fetal Bovine Serum, 1% L-Glutamine, and 1%
Penicillin/Streptomycin (Euroclone) at 37 °C in 5% CO2. Fibroblasts at
60% of confluence were transduced using the CytoTune-iPS 2.0 Sendai
Reprogramming Kit (Thermo-Fisher Scientific) following manufac-
turer's instructions. At day 8, cells were seeded onto a Matrigel-coated
plate (Corning), the next day medium was changed to Nutristem hPSC
XF medium (Biological-Industries) and after 20 days, colonies dis-
playing an ESC-like morphology and positive for Tra-1–60 staining
were manually picked and seeded on Matrigel-coated plates with daily
renewal of the medium, to further expansion and characterization.
iPSCs were manually picked every 5 days and incubated at 37 °C- 5%
CO2.
3.2. Sequencing
Genomic DNA was isolated with QIAmp DNA Bood Mini Kit
(Qiagen). Mutation sequencing was performed by PCR amplification,
using AmpliTaq Gold DNA Polymerase (Thermo-Fisher Scientific) and
IFIH1 primers listed in Table 3.
3.3. Karyotyping
Cells in active cell division were blocked in metaphase adding
10 μg/ml of colcemid to culture medium for 3 h at 37 °C (KaryoMax,
Gibco Co. BRL), detached by trypsin–EDTA, swollen by exposure to
hypotonic KCl solution (0.075M) for 7min at 37 °C, fixed in methanol/
glacial acetic acid (3:1), and dropped on glass slides. Conventional
QFQ-banding at 450–500 bands resolution was performed, according to
the International System for Human Cytogenetic Nomenclature (ISCN
2016). A minimum of 20 metaphase spreads were evaluated for each
sample.
3.4. RNA extraction
Total RNAs was extracted using NucleoSpin RNA II kit (Macherey-
Nagel) and quantified by a spectrophotometer.
3.5. Pluripotency assays: immunofluorescence staining and TaqMan hPSC
scorecard panel
iPSCs were fixed, permeabilized (Fix&Perm-Reagent kit, SIC),
blocked (iBind Buffer, Invitrogen), and incubated with primary anti-
bodies for 3 h at room temperature (RT). Then, cells were washed and
Table 3
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-OCT4 1:400 Thermo Fisher Scientific, Cat# A-13998. RRID: AB_2534182
Pluripotency Markers Mouse anti–TRA–1–60 1:100 Thermo Fisher Scientific, Cat# 4110000. RRID: AB_2533494
Secondary antibodies Goat anti rabbit IgG (H+ L) Alexa Fluor 568 1:300 Thermo Fisher Scientific, Cat# A-11011. RRID: AB_143157
Secondary antibodies Goat anti mouse IgG (H+L) Alexa Fluor 488 1:300 Thermo Fisher Scientific, Cat# A-11001. RRID: AB_2534069
Differentiation RT-qPCR assays with TaqMan chemistry
Target Probe
Ectoderm PAX6 Hs.PT.58.25914558
SOX1 Hs.PT.58.28041414.g
Mesoderm ACTA2 Hs.PT.56a.2542642
CXCR4 Hs00607978_s1
NCAM1 Hs.PT.58.39694135
Endoderm GATA4 Hs.PT.58.259457
SOX17 Hs.PT.58.24876513
Housekeeping gene ACTB Hs.PT.39a.22214847
Primers
Target Forward/Reverse primer (5′−3′)
Genus Mycoplasma (GSO/MGSO) 16S rRNA GGGAGCAAACAGGATTAGATACCCT/TGCACCATCTGTCACTCTGTTAACCTC (268 nt)
Targeted mutation analysis IFIH1 (exon 13) TGAAGACTGGCATGCTGAACAA/CAGAGATATCAATGGCAACCA (360 nt)
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incubated with secondary antibodies for 1 h at RT (Table 3). Nuclei
were stained with Hoechst 33342 (Thermo-Fisher Scientific). Cells were
visualized under inverted fluorescence microscope (Olympus IX70),
with the Image-Pro-Plus software v7.0 (Media Cybernetics).
For a deeper characterization, RNAs were sent to CellModel Services
(Thermo-Fisher Scientific) that allows verification of pluripotency using
The TaqMan hPSC Scorecard Panel.
3.6. Differentiation capability
Clones were differentiated in vitro according to the StemMACS
Trilineage Differentiation Kit protocol (MACS Miltenyi Biotec). Briefly,
iPSCs were dissociated into single cells and seeded on Matrigel-coated
24-well plates (105, 8× 104, 1,3× 105 cells for ectoderm, mesoderm,
and endoderm, respectively) in specific media. At day 7, cells were
collected for RNA extraction and cDNA synthesis with ImPromII
Reverse Transcription System (Promega). Differentiation capability was
evaluated by qPCR with lineage specific markers (Table 3), using
TaqMan Probes (Thermo-Fisher Scientific) and iQ-MPLX powermix on
CFX96 C1000 Touch Real-Time PCR Detection System, with CFX
manager software v.3.1 (Bio-Rad). The relative quantification of target
genes was calculated by the 2^−ΔΔCt method, using ßACTIN as
housekeeping gene.
3.7. Mycoplasma detection
The absence of mycoplasma contamination was confirmed by PCR
amplification (Table 3).
3.8. STR analysis
Fibroblasts and iPSCs were authenticated using AmpFlSTR
Identifiler Plus (Life-Technologies) following the manufacturer's in-
structions.
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